Back to catalogue
№ 008 25 filings · 2023-06-27 → 2026-06-29

ACUITY RM GROUP PLC

ACRM
Technology Share price 0.70p Market cap £2.16m Overall fit 320 /1000

Sub-scale but genuine cybersecurity SaaS with some AI angle and cheap headline multiple; fails the downside-protection test due to chronic dilution, tiny scale and unproven revenue growth — a partial fit for the strategy, not a focus name.

Fair value range 1p–2p Mid case · £4.50m
Absolute upside +108.2% vs current market cap
Conviction 2/5 confidence in undervalued call
Supports the call
  • Clean subscription model with 86% recurring revenue and audited disclosure
  • Net cash balance sheet and demonstrated cost restructuring (Q4 2025 profitable)
  • SaaS multiple methodology corroborated by management's own goodwill impairment test
Limits the call
  • Fair value highly sensitive to unproven growth from AI-native product and STREAM Cloud
  • Repeated dilution at successively lower prices erodes per-share value
Methodology

EV/Sales with haircut vs. SaaS peers, sanity-checked against goodwill impairment model

In one line · bull case

Cheap cybersecurity SaaS at ~1x sales, with genuine cost restructuring visible and optionality on an AI-native product — but only for investors comfortable with microcap execution and dilution risk.

In one line · biggest risk

Continued flat revenue forces another dilutive raise at a lower price, permanently impairing per-share value regardless of enterprise-value fair value.

Drivers
AI beneficiary 45 /100
Cybersecurity GRC sits on the AI-beneficiary list; AI-native product in development but unlaunched — marketing language ahead of demonstrated revenue.
Operating leverage 70 /100
87% gross margin, high subscription mix and fixed cost base give strong theoretical leverage, but £2.1m revenue base is too small for surprises to matter in absolute terms yet.
Earnings vs expectations 30 /100
Revenue flat, NextGen STREAM slipped ~8 months, management commentary consistently more upbeat than realised numbers.
Growth momentum 35 /100
Revenue essentially flat 2024–2025; contracted forward revenue up modestly to £2.1m; Q1 2026 revenue £441k = ~£1.76m annualised (slight decline).
Moat 25 /100
20-year platform, sticky public-sector installs and ISO 27001 credentials, but sub-scale and outgunned by enterprise GRC vendors — moat is narrow.
Earnings quality 45 /100
Goodwill (£5.15m) dominates net assets; R&D capitalisation of £302k in 2025 flatters reported margins vs. cash burn; recurring exceptional items.
Management quality 40 /100
New CEO has delivered cost cuts credibly; capital allocation record is weak — repeated dilutive raises at falling prices.
Cyclicality 25 /100
Subscription software serving regulated / compliance-driven demand — low cyclicality.
Leverage 15 /100
Net cash position: £322k cash vs. £129k loans plus £0.45m recent raise — fortress-lite balance sheet, though burn history is worrying.
Value-trap signals · 6
  • Revenue flat for three consecutive years despite Rizikon acquisition
  • Repeated equity raises at successively lower prices (3.5p → 1.0p → 0.75p)
  • Multiple product launch delays (NextGen STREAM slipped ~8 months)
  • Goodwill £5.15m > net assets of £4.29m — modest impairment would wipe reported equity
  • Broker turnover (WH Ireland/Peterhouse both replaced)
  • Rizikon vendor (Crossword Cybersecurity) went into administration — cautionary reference for segment economics at sub-scale

ACUITY RM GROUP PLC (ACRM) — Research Note

Executive summary

Acuity is a sub-scale UK cybersecurity GRC software microcap (£2.1m market cap) whose STREAM® platform is used by ~70 mostly public-sector clients, with 86% subscription revenue and a newly-launched cloud edition (STREAM® Cloud, March 2026) plus a promised AI-native Risk OS product. Over the past two years the story has been one of aggressive cost restructuring under new CEO David Rajakovich (2025 admin costs down 33% to £2.0m, operating loss cut from £1.08m to £0.19m, Q4 2025 profitable) but essentially flat revenue at £2.1m and repeated dilutive equity raises. The single most important valuation point is that the equity trades at roughly 1x sales — cheap versus SaaS peers, but justified by execution risk, sub-scale unit economics and a track record of missed product timelines and shareholder dilution.

Fair value estimate

  • Range: 0.9p – 1.6p per share (mid ~1.25p), implying an equity value range of £3.3m – £5.8m.
  • Methodology: EV/Sales, sanity-checked against management's own goodwill impairment test (which uses the SaaS Capital index at 3.6x, less a size/quality haircut). At £2.1m revenue and £0.2m net cash post-raise, applying 1.5x–2.5x sales (a 40–60% haircut to the sector multiple to reflect microcap illiquidity, recent losses, execution risk and dilution) yields £3.3m–£5.5m equity value. A DCF is unreliable given the fragile cost/revenue base and dependency on the not-yet-launched AI product.
  • Vs. current £2.1m market cap: implied upside ~60% at midpoint (range +55% to +180%).
  • The 2026 fundraise adds ~60.5m shares (bringing count towards ~370m) which dilutes per-share values marginally.

Sector context

  • Technology / Application Software (cybersecurity GRC subsector) — confirmed.
  • Below typical peers on every quality axis: revenue an order of magnitude smaller, still loss-making, meaningfully dilutive share issuance, weaker sales productivity than scaled peers.
  • Comparables (all much larger): Archer (private), OneTrust (private), MetricStream (private); listed adjacent names include ServiceNow (GRC modules) and — closer to size — LSE-listed Intelligent Ultrasound-type microcaps and Crossword Cybersecurity (the seller of Rizikon to Acuity, which subsequently entered administration — a cautionary reference).

Investment thesis (3 bullets)

  • Operating turnaround visible in the numbers: admin costs cut 33% year-on-year, Q4 2025 operating profit achieved and sustained into Q1/Q2 2026, subscription mix now 86%, £2.1m contracted forward revenue provides near-term visibility 2026-06-29 Final Results; 2026-04-23 Q1 trading update.
  • Priced at roughly 1x sales with high-gross-margin recurring revenue and net cash — a rare valuation discount versus SaaS peers and management's own impairment model (which supports a £7.3m goodwill recoverable) 2026-06-29 Final Results, note 12.
  • Optionality on AI-native Risk OS (Q4 2026 launch planned) and the recently-launched STREAM® Cloud (March 2026), both targeting a fast-growing cyber GRC mid-market historically served by spreadsheets 2026-04-23 Q1 update; 2026-06-29 Final Results.

Key risks (3 bullets)

  • Chronic dilution: shares outstanding roughly doubled from ~121m (Dec-2023) to ~305m (Dec-2025), with a further ~60m issued in June 2026 at 0.75p plus matching warrants — every fundraise is at a lower price 2026-06-29 Final Results, note 19; 2024-06-17 Placing.
  • Product delivery track record is patchy: NextGen STREAM® slipped from July 2025 to March 2026; management flagged in the 2025 H1 statement that "further development" was needed — customers have deferred; goodwill (£5.15m) rests on growth assumptions that have not been demonstrated 2025-09-02 Half-year Report; 2026-01-13 Trading Statement.
  • Sub-scale customer base with concentration risk: ~70 customers, £2.1m revenue implies average contract ~£30k; loss of one large public-sector or defence customer would be immediately visible in results (not disclosed but inferred from filings).

Operating leverage

Acuity has genuine software operating leverage in theory: 87% gross margin (2025: £1.82m GP on £2.10m revenue), a fixed admin cost base of ~£1.8m annualised (Q4 2025 run rate) and 86% subscription revenue. Incremental subscription revenue would drop through at 85%+ contribution margin — a 20% revenue beat (£420k) could realistically add £300–350k to operating profit, taking the business from ~£0 EBIT to £300k+ EBIT. However, the base is so small that operating leverage is dwarfed by absolute execution: the company needs revenue to grow, not just be surprised, before leverage means anything material. Fixed R&D capitalisation (£302k of staff costs capitalised in 2025) also flatters near-term margins vs. cash generation. Genuine SaaS-style operating leverage requires revenue to breach ~£3–4m; current trajectory does not clearly get there in FY26 2026-06-29 Final Results, notes 2, 3.

Value-trap signals

  • Revenue essentially flat over three reported years (2024: £2.13m; 2025: £2.10m; H1 2025 up 10% on H1 2024 but full-year did not accelerate).
  • Repeated dilutive raises at successively lower prices (3.5p in 2024, 1.0p in May 2025, 0.75p in June 2026).
  • Multiple product timeline slips (NextGen STREAM® delayed by ~9 months).
  • Rizikon acquisition (Nov 2024) added acquired customers but the seller (Crossword Cybersecurity) went into administration — a warning about the segment's economics at sub-scale.
  • Goodwill £5.15m accounts for 120% of net assets; a modest impairment would eliminate reported equity.
  • Broker turnover (WH Ireland → Zeus; Peterhouse → AlbR) is a mild governance flag.

Earnings vs. expectations

The filings do not disclose sell-side consensus (unsurprising at this scale). Against management's own commentary: 2025 revenue was described as "in line" but the going-concern note explicitly acknowledges "lower than hoped revenue growth". NextGen STREAM® missed its July 2025 target and re-launched as STREAM® Cloud in March 2026 (~8 months late). H1 2025 revenue grew 10% but full-year 2025 was flat, implying H2 was weaker than H1. Pattern: management execution generally trails commentary; cost commitments have been delivered, revenue commitments have not.

Conviction

Conviction: 2 (low)

Anchoring factors: (i) a small, well-disclosed business with audited accounts and a clean subscription-revenue model; (ii) the SaaS multiple approach gives a defensible upper bound and management's own impairment work agrees; (iii) net cash position removes one tail risk.

Limiting factors: (i) fair value is highly sensitive to the growth trajectory of a business that has been flat for three years; (ii) the AI-native product is a real option but unlaunched — its inclusion or exclusion swings fair value materially; (iii) ongoing dilution means per-share value keeps re-basing lower.

Filings consulted · 25

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-06-29Final Results 2025 Investor Presentation Via2026-06-29_9642667_final-results-2025-investor-presentation-via.md1.00
  2. 2026-06-29Final Results2026-06-29_9640673_final-results.md1.00
  3. 2026-04-24Trading Statement2026-04-24_9536223_trading-statement.md0.85
  4. 2026-04-23Trading Statement2026-04-23_9533999_trading-statement.md0.85
  5. 2026-01-15Statement RE Investor Presentation 10 00am 212026-01-15_9354703_statement-re-investor-presentation-10-00am-21.md0.59
  6. 2026-01-13Trading Statement2026-01-13_9349276_trading-statement.md0.72
  7. 2025-09-05Statement RE Investor Presentation 10 00am 112025-09-05_9090346_statement-re-investor-presentation-10-00am-11.md0.59
  8. 2025-09-02Half Year Report2025-09-02_9083887_half-year-report.md0.77
  9. 2025-07-30Result OF Agm2025-07-30_9013298_result-of-agm.md0.20
  10. 2025-07-07Annual Report And Notice OF Agm2025-07-07_8967277_annual-report-and-notice-of-agm.md0.62
  11. 2025-07-02Statement RE Final Results2025-07-02_8958883_statement-re-final-results.md0.65
  12. 2025-06-25Final Results2025-06-25_8947165_final-results.md0.65
  13. 2025-03-06Statement RE Investor Presentation2025-03-06_8765923_statement-re-investor-presentation.md0.46
  14. 2025-02-04Trading Statement2025-02-04_8719849_trading-statement.md0.55
  15. 2024-11-19Acquisition2024-11-19_8558108_acquisition.md0.49
  16. 2024-09-18Investor Presentation Via Investor Meet Compa2024-09-18_8422400_investor-presentation-via-investor-meet-compa.md0.46
  17. 2024-09-16Half Year Report2024-09-16_8417555_half-year-report.md0.58
  18. 2024-07-10Notice OF Agm Result2024-07-10_8304692_notice-of-agm-result.md0.14
  19. 2024-07-10Agm Statement2024-07-10_8302965_agm-statement.md0.18
  20. 2024-06-17Result OF Placing And Subscription2024-06-17_8262759_result-of-placing-and-subscription.md0.32
  21. 2024-06-17Proposed Placing And Subscription2024-06-17_8261759_proposed-placing-and-subscription.md0.32
  22. 2024-06-17Correction Result OF Placing And Subscription2024-06-17_8263681_correction-result-of-placing-and-subscription.md0.32
  23. 2023-09-28Half Year Report2023-09-28_7783269_half-year-report.md0.41
  24. 2023-09-28Final Results2023-09-28_7783252_final-results.md0.45
  25. 2023-06-27Result OF Agm2023-06-27_7597830_result-of-agm.md0.07

This research note was authored by a large language model after reading 25 regulatory filings published between 2023-06-27 and 2026-06-29. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.